Literature DB >> 4127652

Implications of the treatment of myelomeningocele for the child and his family.

G M Hunt.   

Abstract

Entities:  

Mesh:

Year:  1973        PMID: 4127652     DOI: 10.1016/s0140-6736(73)92881-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Long-term outcome in open spina bifida.

Authors:  Pippa Oakeshott; Gillian M Hunt
Journal:  Br J Gen Pract       Date:  2003-08       Impact factor: 5.386

2.  Perineal sensation: an important predictor of long-term outcome in open spina bifida.

Authors:  P Oakeshott; G M Hunt; R H Whitaker; S Kerry
Journal:  Arch Dis Child       Date:  2006-08-30       Impact factor: 3.791

3.  The failures of success. 1977.

Authors:  Ernest M Gruenberg
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

4.  Handicap and social status of adults with spina bifida cystica.

Authors:  K Evans; V Hickman; C O Carter
Journal:  Br J Prev Soc Med       Date:  1974-05

5.  Screening for spina bifida cystica. A cost-benefit analysis.

Authors:  S Hagard; F Carter; R G Milne
Journal:  Br J Prev Soc Med       Date:  1976-03

6.  The influence of the birth of a malformed child on the mother's further reproduction.

Authors:  R G Record; E Armstrong
Journal:  Br J Prev Soc Med       Date:  1975-12

7.  Some sources of stress found in mothers of spina bifida children.

Authors:  B Tew; K M Laurence
Journal:  Br J Prev Soc Med       Date:  1975-03

8.  Lifestyle in adults aged 35 years who were born with open spina bifida: prospective cohort study.

Authors:  Gillian M Hunt; Pippa Oakeshott
Journal:  Cerebrospinal Fluid Res       Date:  2004-12-10

9.  Neurological level at birth predicts survival to the mid-40s and urological deaths in open spina bifida: a complete prospective cohort study.

Authors:  Pippa Oakeshott; Fiona Reid; Alison Poulton; Hugh Markus; Robert H Whitaker; Gillian M Hunt
Journal:  Dev Med Child Neurol       Date:  2015-02-12       Impact factor: 5.449

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.